Developer docs
API playgroundTry for free, no card

Search company profiles

HERAN Partners

Full company profile

uuid0006eif

Namestring
HERAN Partners
Legal namestring
HERAN Partners
Company typeenum
Private
Founded yearint
2020
Descriptiontext

HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests in early-stage medtech and healthtech companies across Europe. The firm deploys capital through two vehicles: HERAN HealthTech Fund I (€75.5 million closed, fully deployed across 15 companies in Belgium, the Netherlands and the UK with over 30% reported IRR and four exits) and HERAN HealthTech Fund II (€90 million closed, targeting €110-120 million, with first investments into Pharmacelera and Fluidic Sciences). HERAN targets seed, Series A and Series B opportunities in enabling technologies — including AI-assisted medical imaging, quantum-mechanics-based drug discovery, hyperspectral imaging, spatial omics, and clinical workflow optimisation — with B2B commercialisation pathways and a strong clinical backbone.

The firm operates without proprietary technology products; its core offering combines capital with active engagement, mentorship, board participation, and a network spanning academic institutes (notably KU Leuven Research & Development), corporates, and other venture investors. Distribution and deal sourcing run through a pitch submission portal, the Innovate UK Investor Partnerships Programme, an annual Investor Day, and direct outreach by an 11-person team based in Antwerp. Strategic investors in Fund II include the European Investment Fund (€20M cornerstone), PMV (€10M, doubled from Fund I), BNP Paribas Fortis, Finance&Invest Brussels, KU Leuven Research & Development, and a cohort of entrepreneurs and portfolio-company founders.

HERAN's revenue model is conventional asset management economics: a percentage-based management fee on committed or invested capital across both funds, plus carried interest on profitable exits. Fund I's exits (Bluebee to Illumina, PharmaFluidics to Thermo Fisher Scientific, UgenTec to Summa Equity, icometrix to GE Healthcare) demonstrate that the firm's primary "customers" — limited partners and portfolio companies — are served through capital allocation plus hands-on operational support rather than product sales, and Fund II is structured under SFDR Article 8 with ESG due diligence across the investment lifecycle.

Short descriptiontext

HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests at seed to Series B in European medtech and healthtech companies with two funds totalling over €165 million in assets under management.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAntwerp, Belgium
HQ citystring
Antwerp
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, healthcare investments, medtech venture capital, life sciences funding, healthtech fund management
NAICS code2 codes
  • All Other Financial Investment Activities52399
  • Other Financial Investment Activities5239
SIC code2 codes
  • Finance Services6199
  • Investment Advice6282
Product category
Venture Capital Fund Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Fund Management
TypeManaged Services
Description

HERAN generates returns through management fees and carried interest from fund investments. Fund I (HERAN HealthTech Fund I) closed at €75.5 million and invested in 15 companies across Belgium, the Netherlands and the UK, achieving an IRR of over 30% with four successful exits (Bluebee, PharmaFluidics, UgenTec, and icometrix). Fund II (HERAN HealthTech Fund II) has raised €90 million closing with a target of €110-120 million.

heranpartners.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HERAN Partners is a specialist venture capital firm that invests venture and growth capital in early-stage healthcare, medtech, and life sciences companies across Europe. The firm manages dedicated HealthTech funds that deploy capital at seed, Series A and Series B stages into enabling technologies with strong clinical backbones and B2B commercialization strategies, complemented by mentorship, network access and operational support to portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 30% IRR delivered by HERAN HealthTech Fund I
+2 more records
Product overview1 text field

HERAN Partners is a specialist venture capital firm that provides investment products rather than traditional technology products. The firm operates two main investment vehicles: HERAN HealthTech Fund I (€75.5 million) and HERAN HealthTech Fund II (currently €90 million, targeting €110-120 million). These funds invest in early-stage medtech and healthtech companies across Europe, focusing on enabling technologies in healthcare and life sciences. The firm also offers mentorship, hands-on support, and operational expertise to portfolio companies as part of its investment approach.

Product and service2 records
1HERAN HealthTech Fund I
CategoryVenture Capital Fund
Description

HERAN's first venture capital fund (€75.5M) targeting early-stage medtech and healthtech companies in Europe. Invested in 15 companies across Belgium, the Netherlands, and the UK, achieving over 30% IRR with four successful exits (Bluebee acquired by Illumina, PharmaFluidics by Thermo Fisher, UgenTec by Summa Equity, icometrix by GE Healthcare).

2HERAN HealthTech Fund II
CategoryVenture Capital Fund
Description

HERAN's second venture capital fund (€90M closing, targeting €110-120M) investing in early-stage medtech and healthtech companies across Europe. First investments made in Pharmacelera (Spain) and Fluidic Sciences (UK), targeting enabling technologies in healthcare and life sciences with B2B commercialization strategies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Innovation arm of Society of American Gastrointestinal and Endoscopic Surgeons. Strategic investment representing strong validation from global surgical community for HyperVision Surgical's technology.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

UK's leading cancer charity providing strategic investment and validation for HyperVision Surgical's surgical intelligence technology aimed at improving cancer surgery outcomes.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-04-29
Description

World's leading independent nanoelectronics R&D hub co-developing HyperVision Surgical's next-generation hyperspectral sensing technology including design, development and manufacturing of new spectral sensor.

Strategic tierTechnologyTypeTechnology or IntegrationAnnounced on2026-04-29
Description

NVIDIA IGX architecture powers HyperVision's HYPERSNAP® real-time AI inference in the operating room, providing high-performance edge computing capabilities.

Strategic tierProgramTypeGTM or Marketing PartnerAnnounced on2026-02-12
Description

UK government initiative supporting innovative UK companies in attracting investment. HERAN Partners is a selected investor in this program for UK-based companies.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Silicon Valley company igniter that formed strategic alliance with Pharmacelera in 2023. Pharmacelera serves as GI's AI drug discovery strategic partner. GI's Chief Scientific Officer Venkat Reddy sits on Pharmacelera's Board of Directors. Pharmacelera's technology has strengthened IP for several GI portfolio companies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Dutch-based early-stage tech and healthtech venture capital fund. Comparable to HERAN in early-stage healthtech focus and as a co-investor (led the Nuclivision round with HERAN), though broader in sector scope.

TypeDirect peer
Description

Dutch venture capital firm investing across technology and healthcare/life sciences with a pan-European mandate. Comparable to HERAN in early-to-growth stage focus and European healthcare exposure.

TypeBroad incumbent
Description

Large Belgian-listed investment company with a long-standing healthcare and life sciences practice. Comparable as a Belgian healthcare investor, but operates as a broader multi-sector platform rather than a dedicated healthcare specialist like HERAN.

TypeDirect peer
Description

Dutch venture capital firm dedicated to early-stage life sciences companies, including therapeutics, medtech and diagnostics. Comparable to HERAN in stage focus (seed/Series A), European footprint, and life sciences specialization.

TypeDirect peer
Description

Belgian-headquartered independent manager of venture capital and growth funds, including the Capricorn Healthtech Fund. Directly comparable to HERAN as a fellow Belgian healthcare-focused VC and co-investor in deals such as Aspect Analytics.

TypeDirect peer
Description

European venture capital firm focused on healthcare and life sciences, with funds spanning early-stage biotech, medtech and digital health. Directly comparable in sector specialization and European scope.

TypeDirect peer
Description

Belgium-based venture capital firm focused on early-stage life sciences companies across therapeutics, diagnostics and medical devices. Closely comparable to HERAN as a fellow Belgian specialist life sciences investor at similar fund scale.

TypeDirect peer
Description

Leading European life sciences venture capital firm investing across biotech, medtech and digital health from seed through growth stages. Directly comparable to HERAN given overlapping healthcare/life sciences thesis and pan-European focus, though at materially larger fund sizes.

TypeDirect peer
Description

European specialist life sciences venture capital firm investing in later-stage therapeutics and medical devices. Comparable to HERAN in sector focus and European geographic orientation.

TypeDirect peer
Description

European private equity and venture capital firm with a dedicated Life Sciences practice investing across Europe. Comparable to HERAN in healthcare focus and European geographic scope, though with a broader platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment10 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HERAN Partners

Venture Capital Fund Managementheranpartners.com

HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests at seed to Series B in European medtech and healthtech companies with two funds totalling over €165 million in assets under management.

What HERAN Partners does

HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests in early-stage medtech and healthtech companies across Europe. The firm deploys capital through two vehicles: HERAN HealthTech Fund I (€75.5 million closed, fully deployed across 15 companies in Belgium, the Netherlands and the UK with over 30% reported IRR and four exits) and HERAN HealthTech Fund II (€90 million closed, targeting €110-120 million, with first investments into Pharmacelera and Fluidic Sciences). HERAN targets seed, Series A and Series B opportunities in enabling technologies — including AI-assisted medical imaging, quantum-mechanics-based drug discovery, hyperspectral imaging, spatial omics, and clinical workflow optimisation — with B2B commercialisation pathways and a strong clinical backbone.

The firm operates without proprietary technology products; its core offering combines capital with active engagement, mentorship, board participation, and a network spanning academic institutes (notably KU Leuven Research & Development), corporates, and other venture investors. Distribution and deal sourcing run through a pitch submission portal, the Innovate UK Investor Partnerships Programme, an annual Investor Day, and direct outreach by an 11-person team based in Antwerp. Strategic investors in Fund II include the European Investment Fund (€20M cornerstone), PMV (€10M, doubled from Fund I), BNP Paribas Fortis, Finance&Invest Brussels, KU Leuven Research & Development, and a cohort of entrepreneurs and portfolio-company founders.

HERAN's revenue model is conventional asset management economics: a percentage-based management fee on committed or invested capital across both funds, plus carried interest on profitable exits. Fund I's exits (Bluebee to Illumina, PharmaFluidics to Thermo Fisher Scientific, UgenTec to Summa Equity, icometrix to GE Healthcare) demonstrate that the firm's primary "customers" — limited partners and portfolio companies — are served through capital allocation plus hands-on operational support rather than product sales, and Fund II is structured under SFDR Article 8 with ESG due diligence across the investment lifecycle.

HERAN Partners firmographics

Firmographics
Name
HERAN Partners
Legal name
HERAN Partners
Website
https://heranpartners.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
HERAN Partners is a Belgium-based specialist venture capital firm founded in 2020 that invests at seed to Series B in European medtech and healthtech companies with two funds totalling over €165 million in assets under management.
Ownership category
akta.pro rank

Where HERAN Partners is headquartered

Location

Headquarters

HQ city
Antwerp
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

HERAN Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Venture Capital Fund Management: HERAN generates returns through management fees and carried interest from fund investments. Fund I (HERAN HealthTech Fund I) closed at €75.5 million and invested in 15 companies across Belgium, the Netherlands and the UK, achieving an IRR of over 30% with four successful exits (Bluebee, PharmaFluidics, UgenTec, and icometrix). Fund II (HERAN HealthTech Fund II) has raised €90 million closing with a target of €110-120 million.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

HERAN Partners product offering

Product offering

Core offering

HERAN Partners is a specialist venture capital firm that invests venture and growth capital in early-stage healthcare, medtech, and life sciences companies across Europe. The firm manages dedicated HealthTech funds that deploy capital at seed, Series A and Series B stages into enabling technologies with strong clinical backbones and B2B commercialization strategies, complemented by mentorship, network access and operational support to portfolio companies.

Product overview

HERAN Partners is a specialist venture capital firm that provides investment products rather than traditional technology products. The firm operates two main investment vehicles: HERAN HealthTech Fund I (€75.5 million) and HERAN HealthTech Fund II (currently €90 million, targeting €110-120 million). These funds invest in early-stage medtech and healthtech companies across Europe, focusing on enabling technologies in healthcare and life sciences. The firm also offers mentorship, hands-on support, and operational expertise to portfolio companies as part of its investment approach.

Differentiator

Problem solved

Functional benefit

Products and services

  • HERAN HealthTech Fund I HERAN's first venture capital fund (€75.5M) targeting early-stage medtech and healthtech companies in Europe. Invested in 15 companies across Belgium, the Netherlands, and the UK, achieving over 30% IRR with four successful exits (Bluebee acquired by Illumina, PharmaFluidics by Thermo Fisher, UgenTec by Summa Equity, icometrix by GE Healthcare).
  • HERAN HealthTech Fund II HERAN's second venture capital fund (€90M closing, targeting €110-120M) investing in early-stage medtech and healthtech companies across Europe. First investments made in Pharmacelera (Spain) and Fluidic Sciences (UK), targeting enabling technologies in healthcare and life sciences with B2B commercialization strategies.

Quantifiable outcome

  • Over 30% IRR delivered by HERAN HealthTech Fund I
  • +2 more outcomes

Companies that use HERAN Partners

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

HERAN Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

HERAN Partners partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered strategic, technology and program.

  • SAGES Ingenuity (SINC Fund)strategicStrategic or Co-development Partner · 29 April 2026Innovation arm of Society of American Gastrointestinal and Endoscopic Surgeons. Strategic investment representing strong validation from global surgical community for HyperVision Surgical's technology.
  • Macmillan Cancer SupportstrategicStrategic or Co-development Partner · 29 April 2026UK's leading cancer charity providing strategic investment and validation for HyperVision Surgical's surgical intelligence technology aimed at improving cancer surgery outcomes.
  • imecstrategicTechnology or Integration · 29 April 2026World's leading independent nanoelectronics R&D hub co-developing HyperVision Surgical's next-generation hyperspectral sensing technology including design, development and manufacturing of new spectral sensor.
  • NVIDIAtechnologyTechnology or Integration · 29 April 2026NVIDIA IGX architecture powers HyperVision's HYPERSNAP® real-time AI inference in the operating room, providing high-performance edge computing capabilities.
  • Innovate UK Investor Partnerships ProgrammeprogramGTM or Marketing Partner · 12 February 2026UK government initiative supporting innovative UK companies in attracting investment. HERAN Partners is a selected investor in this program for UK-based companies.
  • General InceptionstrategicStrategic or Co-development Partner · 1 January 2023Silicon Valley company igniter that formed strategic alliance with Pharmacelera in 2023. Pharmacelera serves as GI's AI drug discovery strategic partner. GI's Chief Scientific Officer Venkat Reddy sits on Pharmacelera's Board of Directors. Pharmacelera's technology has strengthened IP for several GI portfolio companies.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

HERAN Partners competitors and assessment

Company assessment

Emerging players

  • LUMO Labs: Dutch-based early-stage tech and healthtech venture capital fund. Comparable to HERAN in early-stage healthtech focus and as a co-investor (led the Nuclivision round with HERAN), though broader in sector scope.

Direct peers

  • Inkef Capital: Dutch venture capital firm investing across technology and healthcare/life sciences with a pan-European mandate. Comparable to HERAN in early-to-growth stage focus and European healthcare exposure.
  • BioGeneration Ventures: Dutch venture capital firm dedicated to early-stage life sciences companies, including therapeutics, medtech and diagnostics. Comparable to HERAN in stage focus (seed/Series A), European footprint, and life sciences specialization.
  • Capricorn Partners: Belgian-headquartered independent manager of venture capital and growth funds, including the Capricorn Healthtech Fund. Directly comparable to HERAN as a fellow Belgian healthcare-focused VC and co-investor in deals such as Aspect Analytics.
  • Kurma Partners: European venture capital firm focused on healthcare and life sciences, with funds spanning early-stage biotech, medtech and digital health. Directly comparable in sector specialization and European scope.
  • Newton Biocapital: Belgium-based venture capital firm focused on early-stage life sciences companies across therapeutics, diagnostics and medical devices. Closely comparable to HERAN as a fellow Belgian specialist life sciences investor at similar fund scale.
  • Forbion: Leading European life sciences venture capital firm investing across biotech, medtech and digital health from seed through growth stages. Directly comparable to HERAN given overlapping healthcare/life sciences thesis and pan-European focus, though at materially larger fund sizes.
  • Vesalius Biocapital: European specialist life sciences venture capital firm investing in later-stage therapeutics and medical devices. Comparable to HERAN in sector focus and European geographic orientation.
  • Andera Partners: European private equity and venture capital firm with a dedicated Life Sciences practice investing across Europe. Comparable to HERAN in healthcare focus and European geographic scope, though with a broader platform.

Broad incumbents

  • GIMV: Large Belgian-listed investment company with a long-standing healthcare and life sciences practice. Comparable as a Belgian healthcare investor, but operates as a broader multi-sector platform rather than a dedicated healthcare specialist like HERAN.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

HERAN Partners social profiles

Digital presence

HERAN Partners compliance and trust

Trust signal

Compliance1 record

HERAN Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HERAN Partners leadership team

Management profile

Number of profiles

Profiles11 records

HERAN Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HERAN Partners M&A and investment

M&A and investment

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HERAN Partners

What does HERAN Partners do?

HERAN Partners is a specialist venture capital firm that invests venture and growth capital in early-stage healthcare, medtech, and life sciences companies across Europe. The firm manages dedicated HealthTech funds that deploy capital at seed, Series A and Series B stages into enabling technologies with strong clinical backbones and B2B commercialization strategies, complemented by mentorship, network access and operational support to portfolio companies.

Is HERAN Partners a public or private company?

HERAN Partners is a private company. It is classified as management employee owned and is currently operating.

When was HERAN Partners founded?

HERAN Partners was founded in 2020. It employs 11 to 50 people.

Where is HERAN Partners based?

HERAN Partners is headquartered in Antwerp, Belgium, in the Europe region.

How does HERAN Partners make money?

One revenue line is on record: venture Capital Fund Management.

Who are HERAN Partners's main competitors?

LUMO Labs is listed as an emerging player. Direct peers are Inkef Capital, BioGeneration Ventures, Capricorn Partners, Kurma Partners, Newton Biocapital, Forbion, Vesalius Biocapital and Andera Partners. GIMV is listed as a broad incumbent.

Does HERAN Partners have an API?

No public API is recorded for HERAN Partners.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupmagHypervision Surgical raises £17m to reduce surgical leaks with hyperspectral imagingHypervision Surgical raised an oversubscribed £17m Series A to commercialize its hyperspectral imaging platform for surgery. The funds will support clinical deployment of HYPERSNAP, a next-generation sensor with imec, and cloud-enabled AI analytics. The company holds UK and US regulatory clearance for its system.FinSMEsHypervision Surgical Raises £17M in Series A FundingHypervision Surgical, a London-based medical technology company, raised £17M in Series A funding from investors including Angelini Ventures and ZEISS Ventures. The company will use the funds to expand operations and R&D, aiming to integrate its hyperspectral imaging platform into surgical systems.CB InsightsProducts, Competitors, Financials, Employees, Headquarters LocationsPharmacelera, a Barcelona-based deep tech company applying quantum mechanics and AI to drug discovery, closed a €6 million Series A funding round led by Heran Partners with participation from Clave Capital, Inveready, and Bio&Tech Smart Capital. The funding will enable the company to establish a permanent team in the United States and expand the capabilities of its QaiM drug discovery platform. This round follows a 2023 strategic alliance with Silicon Valley-based General Inception, where Pharmacelera became GI's strategic partner for AI-based drug discovery.PharmiWeb.comHERAN Partners Secures €90 Million for European Healthtech FundBelgian venture capital firm HERAN Partners has closed a €90 million fund to invest in early-stage medtech and healthtech companies in Europe. The fund, HERAN HealthTech Fund II, aims to grow closer to €110-120 million and has already made its first investment in a Spanish drug discovery company.LinkedInPharmacelera Secures €6M Funding Round with HERAN PartnersPharmacelera closed a €6 million investment round led by HERAN Partners with participation from Clave Capital, Inveready, and Bio & Tech Smart Capital. The funding will support establishment of a permanent U.S. team and expand capabilities of the company's QaiM engine, a platform combining quantum mechanics and AI for small molecule and peptide drug discovery. The technology reportedly generates molecular candidates up to 10 times better and 75,000 times faster than traditional AI-led approaches.UnquoteHeran Partners nears full deployment of debut fund, mulls next fundraiseHeran Partners, a Belgian health tech VC, has three more investments left in its EUR 75m debut fund, aiming to complete deployment within 18 months. The fund has made 12 investments, three exits, and will likely raise a successor vehicle. It targets seed and Series A companies in the Benelux region.ThironaThirona closes financing round with HERAN Partners and Borski FundThirona has closed a financing round with Belgian investment fund HERAN Partners and the Dutch Borski Fund to accelerate its transition toward market leadership in medical imaging. The company intends to use the proceeds to expand operations and scale up development efforts as it approaches 10 million analyzed images.